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Benefits of an expanded use of plasma
exchange for anti-neutrophil cytoplasmic
antibody-associated vasculitis within a
dedicated clinical service
Neeraj Dhaun1,2*, Andrew Saunders2, Christopher O. Bellamy3, Rocío Martinez Gallardo2, Lynn Manson4
and David C. Kluth2
Abstract
Background: Current recommendations for ANCA-associated vasculitis (AAV) support its management within a
dedicated clinical service. Therapies for AAV are imperfect with many patients failing to achieve disease control and
others experiencing disease relapse. Plasma exchange (PEX) may be beneficial especially when the kidney is involved.
Methods: Within a new, dedicated service we retrospectively assessed, over a 6-year period, the benefits of PEX in two
patient cohorts, discriminated by PEX treatment alone. Patients received PEX alongside standard of care if they fulfilled
any of the following criteria: 1. serum creatinine >500 μmol/l or dialysis-requiring renal failure, 2. alveolar haemorrhage,
3. renal biopsy showing ≥30 % focal and necrotising lesions ± cellular crescents. Outcome measures included disease
remission and relapse, cumulative immunosuppression, and morbidity and mortality.
Results: Of 104 new patients, 58 patients received PEX at presentation, 46 did not. Cyclophosphamide and/or rituximab
dosing was similar for both groups. Although patients receiving PEX had poorer renal function, a higher C-reactive
protein and disease activity score at presentation disease remission rate was similar in both groups (no PEX vs. PEX:
96 % vs. 98 %). The PEX group entered remission quicker (no PEX vs. PEX: 3.9 ± 4.0 vs. 2.8 ± 1.3 months, p < 0.05), with a
lower 3-month cumulative glucocorticoid dose (no PEX vs. PEX: 2.5 ± 0.4 vs. 2.3 ± 0.2 g, p < 0.001). Relapse was similar
between groups but adverse events lower in the PEX group.
Conclusions: PEX may be of benefit in AAV. Larger, longer randomised controlled trials are now needed.
Keywords: ANCA vasculitis, Outcome, Plasma exchange
Background
Systemic vasculitis associated with autoantibodies to
neutrophil cytoplasmic antigens (ANCA) encompasses
granulomatosis with polyangiitis (GPA, previously known
as Wegener’s granulomatosis), microscopic polyangiitis
(MPA) and eosinophilic granulomatosis with polyangiitis
(EGPA, previously known as Churg-Strauss syndrome).
ANCA-associated systemic vasculitis (AAV) has a preva-
lence of 14–30 patients per 100,000 [1] and its most
frequent severe manifestations include rapidly progressive
glomerulonephritis leading to dialysis-requiring renal fail-
ure and alveolar capillaritis leading to pulmonary haemor-
rhage. Given its rare nature current guidelines recommend
referral of all patients with AAV to a specialised service
[2]. In line with this we designed and set up a new clinical
service in our centre with the aim of centralising expertise
to improve patients outcomes, and to facilitate patient par-
ticipation in clinical trials of AAV.
Current standard of care for the initial treatment of AAV
is glucocorticoids in combination with either cyclophospha-
mide (CYC) or the B cell depleting antibody, rituximab.
Despite treatment, however, overall survival in AAV re-
mains poor with many patients suffering chronic morbidity
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including end-stage renal disease [3, 4]. These are consid-
ered to be as a result of ineffective therapy and treatment
toxicity.[4] At least 20 % of AAV patients do not achieve
adequate disease control and an additional ~50 % relapse
within 5 years [5, 6]. These both result in increased im-
munosuppressive burden with its associated risks, most im-
portantly infection [7]. Between 25 and 50 % of patients
with severe AAV have a severe infection within 12 months
of starting treatment and the most common causes of death
are infection and uncontrolled disease activity [8, 9]. Thus,
there is an unmet need for additional therapies that
not only improve disease control but also limit treat-
ment toxicity.
Plasma exchange (PEX) removes circulating plasma con-
stituents including immunoglobulins. Its potential role in
the treatment of AAV has been proposed since the discov-
ery of the pathogenic role of ANCA in AAV [10, 11]. Data
from small studies suggest that PEX may be of benefit in
AAV [12, 13]. Current recommendations for the use of
PEX in AAV include pulmonary haemorrhage [14] and se-
vere renal disease [15]. The latter is defined as either a
serum creatinine >500 μmol/l or dialysis-dependent renal
failure but this is largely based on the MEPEX study [8]
which compared PEX with intravenous methylpredniso-
lone as adjuvants to CYC and oral prednisolone in patients
with a new diagnosis of AAV and severe renal disease.
However, measurement of renal function, using serum
creatinine is inadequate as substantial irreversible renal
tissue damage can occur before function is impaired to a
detectable extent [16]. Histological features of renal in-
jury in AAV include an intense, neutrophil-predominant
inflammatory infiltrate, segmental glomerular necrosis
reflecting a glomerular capillaritis and intra-glomerular
monocyte proliferation contributing to a pauci-immune,
focal and necrotising, crescentic glomerulonephritis [17].
In this first study from our dedicated vasculitis service,
we compared the addition of PEX on top of standard of
care to standard of care alone in patients presenting with
a new diagnosis of AAV. Indications for PEX were either
pulmonary haemorrhage or ‘severe’ renal disease. Im-
portantly, alongside the standard dialysis-requiring renal
failure and serum creatinine criteria we included a histo-
logical definition of severity. Thus, ‘histologically signifi-
cant renal disease’ was also defined as ≥30 % focal and
necrotising lesions with or without cellular crescents on
renal biopsy. Our outcome measures included disease
remission and relapse, morbidity and mortality.
Methods
Design & set-up of a new vasculitis service
All patients with AAV presenting to our unit and those
referred from others were managed in the new specia-
lised vasculitis service covering NHS Lothian & Borders,
a population of ~1 million. The components of this ser-
vice included:
Clinical personnel
Two renal consultants; a single, dedicated renal patholo-
gist to review all renal vasculitis biopsies so minimising
variation in histological data interpretation; two radiolo-
gists able to perform renal and/or lung biopsies within
24–48 h of patient presentation; a supportive plasma ex-
change service headed by an interested haematologist; a
core group of nurses trained to administer biological
agents and intravenous CYC.
Clinical assessments
All inpatients with AAV were reviewed by the vasculitis
team daily; on discharge they were reviewed in the dedi-
cated clinic fortnightly for the first 6 weeks, and then
monthly for the first 6 months; thereafter, clinic attend-
ance was 3-monthly or earlier if needed (suggestion of
disease relapse or disease complications).
Patient support
All AAV patients were given a central email address and
mobile number that they could call or text if they experi-
enced any problems with symptoms or their treatment.
Queries were responded to within 24 h. Patients were also
given the contact details for a national vasculitis patient
support group ‘The Lauren Currie Twilight Foundation’.
See: http://www.thelaurencurrietwilightfoundation.org/
Broader education
To improve general awareness of AAV and of the new
specialised clinical service the two clinicians responsible
for the service gave talks to primary and secondary care
as well as at the patient support group.
Succession planning
Interested trainees from nephrology, neurology, rheuma-
tology and respiratory medicine were invited to under-
take 6-month attachments in the vasculitis service: they
attended clinics, organised treatments and answered pa-
tient queries under the guidance of the lead clinicians.
Study comparing PEX vs. no PEX
Patient population
All patients presenting to the new dedicated service be-
tween September 2006 and April 2013 were included in the
study. Patients were categorised by ANCA status and ex-
tent of organ involvement and followed up for the time
period of the study. Patients positive for both ANCA and
anti-glomerular basement membrane antibody were ex-
cluded from the analysis. As the data presented are a retro-
spective analysis of routine clinical care, the South-East
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Scotland Local Research Ethics Committee advised that this
study did not require ethical approval or patient consent.
Clinical data
Data collection included demographic characteristics, dis-
ease activity and damage assessments, medications, and la-
boratory results at each assessment and severe adverse
events since starting treatment. Disease activity was
graded according to the ‘Birmingham Vasculitis Activity
Score’ (BVAS, scores range from 0 to 63, with higher
scores indicating more active disease) [18] and by in-
vestigators’ assessments of disease activity as remission,
ongoing active disease (treatment failure), or relapse. Re-
mission was defined as a BVAS score of 0 that was main-
tained for 2 months and a prednisolone dosage of ≤10 mg/
day. Treatment failure occurred when remission was not
achieved and disease activity progressed, necessitating add-
itional immunosuppression. Disease relapse was defined as
vital organ-threatening vasculitis activity, such as, disease
of the eyes, lungs, kidneys, or sub-glottis, or other manifes-
tations attributable to active vasculitis necessitating escal-
ation of immunosuppression. Damage related to disease or
treatment was scored according to the ‘Vasculitis Damage
Index’ (VDI, scores for this index range from 0 to 64, with
higher scores indicating more severe damage) [19]. Severe
adverse events were categorised as those resulting in hos-
pitalisations, serious infections – defined as those requir-
ing hospitalisation for intravenous therapy – malignancies,
or death.
Treatment protocols
Plasma exchange (PEX)
All patients were allocated to treatment with PEX along-
side standard of care if they fulfilled any of the following
criteria at presentation: 1. serum creatinine >500 μmol/l
or dialysis-requiring renal failure, 2. alveolar haemorrhage,
3. significant histological renal disease defined as ≥30 %
focal and necrotising lesions ± cellular crescents on renal
biopsy (see Additional file 1: Supplementary Methods for
further information on renal biopsies). PEX consisted of 8
centrifugal exchanges (5 initially given on consecutive days
and then 3 on alternate days). Each exchange comprised
of 60 ml/kg with 4 % human albumin solution used as the
replacement fluid. In patients at risk of bleeding fresh fro-
zen plasma was used as the replacement. All patients re-
ceiving PEX were prescribed supplemental oral calcium
(~2400 mg/day) and cholecalciferol (~40 μg/day).
Glucocorticoids
Oral glucoroticoids were given at a starting dose of 1 mg/
kg/day to a maximum dose of 80 mg/day. The dose
reduction schedule is shown in the Additional file 1:
Supplementary Methods. Pulsed steroids were not used.
Cyclophosphamide (CYC)
Between 2006 and 2007 CYC was given orally at a dose
of 2 mg/kg/day to a maximum dose of 150 mg/day.
From 2007 onwards, intravenous (i.v.) CYC was used
with the dose adjusted for age and renal function (see
Additional file 1: Supplementary Methods).
Rituximab
Rituximab was given as 2 i.v. doses of 1 g given two
weeks apart. Premedication comprised of hydrocortisone
200 mg i.v, paracetamol 1 g oral, and chlorpheniramine
10 mg i.v.
Timing of CYC & rituximab
The first dose of i.v. CYC and/or rituximab was given on
completion of the 5 initial consecutive day PEX and
there was at least 24 h delay between the completion of
either CYC or rituximab and the next PEX.
Mycophenolate mofetil (MMF)
This was prescribed at a dose of 1 g twice a day (b.d.).
Methotrexate
This was given orally at a dose of 5 – 20 mg/week with
co-prescription of folic acid.
Study endpoints
These included disease remission and relapse, time to re-
lapse, cumulative immunosuppressive burden at 3 months,
severe adverse events and all-cause mortality.
Statistical analysis
Statistical analysis was performed using SPSS version 18
and Prism version 6 software. Results are expressed as
actual values and percentages for categorical variables
and as means ± standard deviations or median ± inter-
quartile range for continuous variables. Group compari-
sons were made using Fisher’s exact test, student t-test,
Wilcoxon-Mann–Whitney and one-way analysis of vari-
ance (with repeated measures) where appropriate. Re-
lapses were analysed using Kaplan-Meier survival
analysis, with log rank analysis for significance. P values
less than 0.05 were considered significant.
Results
Specialised Vasculitis Service (Table 1)
Demographic data for the overall group of patients
managed within the vasculitis clinic and classified by
ANCA status are shown in Table 1. The age distribution
of patients at disease presentation is shown in Fig. 1a. 29
patients (28 %) of all incident patients were ≥70 years of
age. When comparing groups by ANCA status, age was
similar as was the number of male and female patients.
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Over the study period the source of patient referral
changed. Up to 2007 incident and prevalent patients
with vasculitis had a similar referral pattern: from
another medical specialty, the general nephrology
clinic, primary care and the emergency department.
Once the vasculitis service had been established for
5 years this changed with most incident patients re-
ferred directly to the service (Fig. 1b). Over the
same time periods, the mean time to renal biopsy
changed from 4.6 to 2.3 days and the median from
2.0 days to 1.0.
Mean and median follow up of all patients were 1001 ±
860 and 772 ± 86 days, respectively. When categorised by
ANCA status, remission rates and time to remission were
similar across groups. In terms of disease relapse, those
with disease associated with PR3 ANCA were more
likely to relapse (PR3 vs. MPO vs. ANCA-: 29 vs. 9 vs.
14 %, p = 0.02 by log rank analysis for both PR3 vs.
MPO and PR3 vs. ANCA-, Fig. 1c).
Outcomes were no different between those patients
who received CYC (n = 68) as part of their initial induc-
tion compared to those who received rituximab (n = 22)
(See Additional file 1: Table S1).
Of the 29 patients who were ≥70 years at presentation
27 were alive at 1 year after the start of treatment (See
Additional file 1: Table S2). Elderly patients were more
likely to be treated with rituximab than younger patients
(age ≥70 vs. <70: 48 vs. 11 %, p < 0.0001).
Table 1 Demographic data, clinical parameters at presentation, treatments given, and outcome data for all patients within the
vasculitis service and also categorised by ANCA subtype
Characteristic PR3+ (n = 51) MPO+ (n = 46) ANCA-a (n = 7) Overall (n = 104)
Age 58 ± 15 64 ± 19 61 ± 4 61 ± 16
Male / Female 26 /25 21 / 25 5 / 2 52 / 52
Renal involvement (%) 45 (88) 44 (96) 4 (57) 93 (89)
At presentation
Creatinine (μmol/l) 225 ± 225 330 ± 239 234 ± 216 272 ± 235
CRP (mg/l) 97 ± 86 73 ± 73 38 ± 40 82 ± 79
Haemoglobin (g/l) 107 ± 23 98 ± 18 114 ± 28 103 ± 22
Dialysis-requiring 9 11 1 21
Induction period (~3 months)
Number (%) of patients receiving
Glucocorticoids 51 (100) 46 (100) 7 (100) 104 (100)
CYC 35 (69) 30 (65) 3 (43) 68 (65)
MMF 9 (18) 18 (39) 2 (29) 29 (28)
Rituximab 6 (12) 15 (33) 1 (14) 22 (21)
Plasma exchange 25 (49) 30 (65) 3 (43) 58 (56)
Cumulative glucocorticoid dose (g) 2.3 ± 0.3 2.4 ± 0.3 2.2 ± 0.0 2.3 ± 0.3
Cumulative CYC dose (g) 6.5 ± 3.2 6.4 ± 3.9 5.3 ± 1.0 6.3 ± 3.4
Remission
Number entering remission (%) 50 (98) 44 (96) 7 (100) 101b (97)
Time to remission (days) 108 ± 184 82 ± 29 124 ± 149 98 ± 136
At 12 months
Creatinine (μmol/l) 124 ± 57 215 ± 193 120 ± 68 158 ± 132
Dialysis-requiring 1 4 0 5
Relapses & mortality
Number of patients with disease relapses (%) 15 (29) 4 (9) 1 (14) 20 (19)
Mean time to first relapse (days) 880 ± 692 1073 ± 877 635 ± 760 953 ± 786
Median time to first relapse (days & IQR) 754 (823) 857 (1252) 223 (1078) 795 (1102)
Number of patients died (%) 5 (10) 4 (9) 0 (0) 9 (9)
ANCA anti-neutrophil cytoplasmic antibody, BVAS Birmingham Vasculitis Activity Score, EGPA eosinophilic granulomatosis with polyangiitis, ENT ear, nose & throat,
GPA granulomatosis with polyangiitis, MPA microscopic polyangiitis, MPO myeloperoxidase, PR3 proteinase-3. Data are shown as number of patients (%), mean ±
standard deviation or median and IQR. aThe 7 patients that were ANCA- had evidence of a pauci-immune necrotising glomerulonephritis on renal biopsy. b3
patients did not enter remission as they died during before this
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PEX vs. no PEX
Within the time period of the study 104 patients pre-
sented with vasculitis. Of these, 58 patients received PEX
as part of their induction treatment, 46 did not. Indica-
tions for PEX at presentation were dialysis-dependent
renal failure, n = 20 (35 %); creatinine >500 μmol/l, n = 12
(21 %); alveolar haemorrhage, n = 9 (16 %); and significant
histological renal disease, n = 32 (55 %).
Demographics of the two patient groups are shown in
Table 2. There were no differences between the two
groups in terms of age, sex distribution, or ANCA status.
Extent of organ involvement was also similar apart from
nerve disease, which was commoner in those that did not
receive PEX. BVAS was higher in those receiving PEX.
Mean follow up was 24.1 ± 21.5 months in the group of
patients receiving PEX and 43.2 ± 32.3 months in those
not receiving it. Follow up >5 years was available for 6 pa-
tients who received PEX and 17 who did not.
A
B
C
Fig. 1 Age distribution, source of referral and relapse-free survival
curves for all study patients. a age distribution at presentation of all
patients cared for within the vasculitis service. Data are shown as %
frequency within each 10-year period. b source of referral of vasculitis
patients up to 2007 (left) and 2009 – 2013 (right). c relapse-free survival
curves for patients in the groups defined by their ANCA status at
presentation (PR3: proteinase-3, red line, n = 51; MPO: myeloperoxidase,
blue line, n = 46; ANCA-: ANCA negative, green line, n = 7). p = 0.02 for
PR3 vs. MPO and for PR3 vs. ANCA- by log rank analysis
Table 2 Baseline demographic data of the groups either receiving
or not receiving plasma exchange (PEX) as part of disease induction
Characteristic No PEX (n = 46) PEX (n = 58) p value
Age (years) 61 ± 15 60 ± 17 0.81
Male / Female 26 / 20 27 / 31 -
ANCA status (%)
PR3+ 26 (57) 25 (43) 0.67
MPO+ 16 (35) 30 (52) 0.07
Negative 4 (8) 3 (5) 0.81
Diagnosis
GPA 26 25 0.67
MPA 12 29 0.02
ANCA- vasculitis 4 3 0.81
EGPA 3 1 0.32
Organ involvement
Number (%) of patients
Kidney 35 (76) 57 (98) 0.47
Lung 26 (46) 30 (52) 0.54
ENT 17 (37) 13 (22) 0.89
Nerve 14 (30) 8 (14) 0.03
Skin 10 (22) 8 (14) 0.26
Joints 7 (15) 11 (19) 0.65
Eye 4 (9) 5 (9) 0.96
Gastrointestinal 1 (2) 3 (5) 0.44
Indication for PEX
Number (%) of patients
Dialysis-requiring renal
failure
- 20 (34)
Serum creatinine
≥500 μmol/l
- 12 (21)a
Alveolar haemorrhage - 9 (16)
Histologically
significant renal disease
- 52 (90)
BVAS 17 (13 – 23) 29 (12 – 47) 0.01
Abbreviations are as for Table 1. Data are given as number of patients (%) with
median and interquartile range shown for BVAS. a10 of these 12 patients
required dialysis at disease presentation
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Disease remission
Table 3 shows the outcome data for the two groups.
Despite the group of patients receiving PEX being sicker
at presentation (as illustrated by poorer renal function, a
greater inflammatory response and higher disease activity
score) disease remission rate was similarly high to the
group that did not receive PEX (no PEX vs. PEX:
96 % vs. 98 %, p = ns). Interestingly, those receiving
PEX entered remission quicker than those who did not (no
PEX vs. PEX: 3.9 ± 4.0 vs. 2.8 ± 1.3 months, p < 0.05). In
those patients receiving PEX, estimated GFR (eGFR)
improved over the 12 months following start of treatment
(0 vs.12 months: 22 ± 22 vs. 43 ± 24 ml/min, p < 0.001),
whereas it did not change in the group not receiving PEX
(0 vs.12 months: 56 ± 31 vs. 55 ± 24 ml/min, p = ns,
Fig. 2a).
At 12 months C-reactive protein, haemoglobin and
serum albumin were normal in both groups and did not
differ between the groups. Of the 20 patients requiring
dialysis at presentation in the PEX group only 5 remained
dialysis-dependent at 12 months. The one patient requir-
ing dialysis in the no PEX group also regained independ-
ent renal function at 12 months.
Cumulative immunosuppression (Table 3)
All 104 patients received glucocorticoids at induction but
the cumulative dose at 3 months was lower in those who
also received PEX than in those that did not (no PEX vs.
PEX: 2.5 ± 0.4 vs. 2.3 ± 0.2 g, p < 0.001). ~80 % of patients
who were treated with PEX were also treated with CYC,
whereas CYC was the induction immunosuppression of
choice in ~50 % of the non-PEX group. Cumulative CYC
dose was ~30 % lower in the PEX group than in the non-
PEX group (p < 0.01), likely related to poorer renal func-
tion in the PEX group. Rituximab use was commoner in
the group not receiving PEX (33 vs. 12 %), although over-
all, both groups did not differ in whether they received
CYC and/or rituximab.
Disease relapse (Table 3)
Relapse rates were similar between the groups as was
the time to first relapse (no PEX vs. PEX: 26 vs. 14 %
and 23.8 ± 13.3 vs. 18.8 ± 10.6 months, p = ns for both,
Fig. 2b).
Adverse events
Table 4 shows the adverse events for the two groups.
Of the 58 patients receiving PEX, 3 experienced symp-
tomatic hypocalcaemia – mean corrected serum calcium
was 1.96 ± 0.14 mmol/l. Although PEX was started at
least 24 h following a renal biopsy 2 patients had signifi-
cant post-biopsy bleeds that required blood transfusion.
There were no episodes of central venous cannula
infection.
Table 3 Clinical parameters at presentation, treatments given,
and outcome data for the two groups either receiving or not
receiving plasma exchange (PEX) as part of disease induction
Characteristic No PEX
(n = 46)
PEX (n = 58) p value
At presentation
Creatinine (μmol/l) 140 ± 90 370 ± 259 0.000
eGFR (ml/min/1.73 m2) 56 ± 31 22 ± 22 0.000
CRP (mg/l) 48 ± 61 105 ± 82 0.001
Haemoglobin (g/l) 116 ± 21 94 ± 18 0.000
Albumin (g/l) 34 ± 6 29 ± 6 0.000
Dialysis-requiring 1a 20 0.000
VDI 0 0 1
Induction period (~3 months)
Number (%) of patients receiving
Glucocorticoids 46 (100) 58 (100) 1
CYC 23 (50) 45 (78) 0.004
Rituximab 15 (33) 7 (12) 0.03
CYC and/or rituximab 38 (83) 52 (90) 0.39
MMF 8 (17) 16 (28) 0.24
Methotrexate 8 0 0.001
Azathioprine 6 1 0.02
Infliximab 1 0 0.25
Cumulative glucocorticoid
dose (g)
2.5 ± 0.4 2.3 ± 0.2 0.000
Cumulative CYC dose (g) 8.0 ± 3.6 5.4 ± 3.0 0.002
Disease remission
Number (%) entering
remission
44 (96) 57 (98) 0.98
Time to remission (days) 118 ± 124 83 ± 39 0.046
At 12 months
Creatinine (μmol/l) 120 ± 46 191 ± 172 0.02
eGFR (ml/min/1.73 m2) 56 ± 24 43 ± 24 0.02
CRP (mg/l) 22 ± 71 8 ± 14 0.33
Haemoglobin (g/l) 126 ± 14 121 ± 15 0.15
Albumin (g/l) 41 ± 6 40 ± 5 0.31
Dialysis-requiring 0 5 0.04
VDI 1.2 ± 0.2 1.3 ± 0.1 0.79
Disease relapse
Number (%) of patients with
relapses
12 (26) 8 (14) 0.09
Mean time to first
relapse (days)
714 ± 699 564 ± 318 0.38
Median time to first relapse 800 (1124) 773 (1164) 0.57
(days & IQR)
CRP C-reactive protein, CYC cyclophosphamide, eGFR estimated glomerular
filtration rate, IQR interquartile range, MMF mycophenolate mofetil, VDI
Vasculitis Damage Index. Data are shown as either mean ± standard deviation or
median and IQR. aThis patient did not receive PEX as it was not tolerated
alongside dialysis
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There were 15 serious adverse events in 12 of the 58
patients (21 %) receiving PEX and 21 events in 15 of the
46 patients (33 %) who did not receive PEX. The cat-
egorisation of these events is shown in Table 4. The total
number of adverse events was lower in the PEX group
(p = 0.04).
Discussion
The evidence base for the treatment of AAV has been
transformed over the last 15 years. Clinical trials have
shown the effectiveness of cytotoxic drugs [20, 21],
plasma exchange [8] and biological agents [9, 22]. How-
ever, clinical trials are often conducted in a controlled
environment and results in everyday clinical practice can
be very different [23]. Furthermore, many trials require
stringent entry criteria to be met for subject inclusion
and if these are rigidly applied to clinical practice it can
often result in many patients missing out on potentially
beneficial treatments. The current data represent our
clinical experience in establishing a specialised service
for the care of patients with AAV, which is a rare disease
that has ‘orphan’ status in both the US and EU. The ser-
vice involved a centralised clinic run by a small cohort
of dedicated clinicians. Based on trial data and our own
experience we developed local protocols for the manage-
ment of AAV with the aim of optimising the clinical care
and outcomes of patients with AAV. Our results suggest
that those with AAV may benefit from PEX, with its ex-
panded use based on histological criteria as well as the
more conventional clinical and functional markers. PEX
resulted in equivalent remission rates compared to non-
PEX patients, despite those receiving PEX having more
severe disease at presentation. Additionally, remission
was achieved more rapidly and the cumulative steroid
dose was lower. This latter finding likely explains the
fewer adverse events in those receiving PEX.
The MEPEX trial compared PEX with intravenous
methylprednisolone to the then standard of care in pa-
tients with AAV who were either dialysis-dependent or
had a serum creatinine >500 μmol/l at presentation [8].
The main outcome of the study was that there was a re-
duced incidence of dialysis-dependent renal failure at 3
and 12 months, although no difference in mortality was
observed. Interestingly, longer-term data from this study
suggest that PEX confers no survival benefit [24].
MEPEX only included patients with very poor renal
function. Furthermore, it used serum creatinine as its
surrogate measure of GFR. This is a poor measure of
renal function [16] and based on this alone MEPEX
would have excluded many patients with a similar GFR
to those included. This is an issue particularly in older
patients [25]. Bearing this problem in mind we applied
Fig. 2 Change in eGFR and relapse-free survival curves for PEX vs. no
PEX patients. a change in abbreviated 4-variable MDRD estimated
glomerular filtration rate (eGFR) over the 12 months since starting
treatment. Data are shown as mean ± standard deviation. Blue circles:
received no plasma exchange (PEX); red squares: received PEX. At each
time point eGFR was different between the two groups (p < 0.05) based
on a repeated measures ANOVA. Between 0 and 12 months there was
no change in eGFR in the no PEX group whereas eGFR improved in
the PEX group (p < 0.001). b relapse-free survival curves for patients in
the group receiving plasma exchange (PEX, red line, n= 58) up to
6 years and for those not receiving it (blue line, n = 46) up to 10 years.
p = 0.64 by log rank analysis
Table 4 Serious adverse events for the groups either receiving
or not receiving plasma exchange (PEX) as part of disease
induction. Data are given as number of patients (%)
Severe adverse events
Number (%)
No PEX
(n = 46)
PEX
(n = 58)
p value
All severe adverse events
Number of adverse events 21 15 0.04
Number (%) of patients 15 (33) 12 (21) 0.26
Serious infections, number
of events
10 7 0.29
Chest 6 5 0.53
Urine 2 2 1
Pneumocystis jirovecii pneumonia 2 0 0.19
Other hospitalizations,
number of events
4 5 1
Fractures 2 2 1
Cardiovascular 2 3 1
Malignancy 2 0 0.19
Death 5 3 0.46
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renal biopsy criteria to identify patients with ‘severe renal
disease’ who might benefit from PEX. Although previous
classifications have used ≥50 % glomeruli affected as a def-
inition of severe renal disease this is arbitrary and prone
to significant disease mis-classification depending on the
adequacy of the renal biopsy. We defined ‘severe’ by the
presence of ≥30 % focal and necrotising lesions in the
presence or absence of cellular crescents on renal biopsy.
In the MEPEX study, analysis of those patients who had
renal biopsies suggested that ~80 % of glomeruli showed
these histological features. Applying our broader criteria,
98 % of PEX patients achieved remission at a median
interval of 2.8 months and eGFR improved from 22 ml/
min at presentation to 44 ml/min at 12 months. Further-
more, 15 of the 20 dialysis-dependent patients were dialy-
sis independent by 12 months. PEX was well tolerated
with fewer adverse events compared to non-PEX treated
patients despite more severe disease at presentation. Inter-
estingly, our findings are similar to those of MEPEX with
identical disease relapse rates.
There is significant evidence that ANCA are patho-
genic [26]. They are able to activate neutrophils, causing
production of reactive oxygen species and degranulation
[27] and can cause endothelial injury [28]. Furthermore,
animal models have shown that MPO antibodies and
anti-MPO specific T-cells can induce a crescentic glom-
erulonephritis and lung disease [10, 29]. Thus, there is
biological plausibility in believing that an early reduction
in circulating ANCA titre may translate to clinical benefit.
This may then partly explain why the cohort of patients
receiving PEX achieved disease remission more rapidly.
Unfortunately, we did not have a sufficient number of
ANCA titres from the early treatment period to compare
how they changed between the two groups. As with other
studies [20, 28], we found distinct clinical phenotypes de-
pending on the type of ANCA present. MPO positive pa-
tients presented with a higher serum creatinine and had
worse renal function at 12 months, whereas PR3 positive
disease was more likely to relapse [22, 30].
During the course of our study a number of clinical trials
were published comparing the use of rituximab with cyclo-
phosphamide for inducing disease remission [9, 22, 31].
Consistent with these data we found rituximab to be as ef-
fective as cyclophosphamide for the early treatment of dis-
ease (without an excess of adverse events) and so this
study further supports the case for rituximab to be consid-
ered as standard of care for the initial treatment of AAV.
This also fits with evidence that it is glucocorticoid dose
during disease induction that is most linked to the increase
in infection risk rather than the cytotoxic or biological
agent is used [32].
AAV is increasingly identified in older patients, many
of whom will have additional co-morbidities [33, 34]. In
our population the annual incidence of AAV is ~58
cases per million of population in patients ≥70 years of
age compared to ~20 per million in those <70. Our data
also suggest that ~30 % of new cases of AAV occur in
those >70 years. Overall, this age group represents ~12 %
of our population. Our own practice has been to use ritux-
imab in patients over the age of 70 alongside lower doses
of glucocorticoids with the aim of reducing early infective
complications [9, 31]. These patients had similar remission
rates and 1 year survival compared to the younger cohort.
Our data provide further evidence to support treatment
with immunosuppression of older patients presenting with
AAV [35], as well as the need to educate healthcare profes-
sionals about identifying disease in the elderly.
Providing a centralised clinical service for vasculitis
has a number of inherent advantages. It allows the de-
velopment of clinical expertise for a rare disease allow-
ing prompt application of evidence based practice and
will provide a forum for education of both patients and
health professionals to facilitate more rapid specialist refer-
ral. Once the clinical service was established more than
half the patients were directly referred to the vasculitis
clinic. This resulted in more rapid diagnosis, appropriate
investigation and initiation of treatment. The outcomes of
our clinical service compare favourably with data from
other vasculitis studies. We found that >95 % of our pa-
tients achieve disease remission by 3 months compared to
80-85 % of patients in most studies of either cyclophospha-
mide or rituximab. Major disease relapse occurred in 29 %
of PR3 positive patients, 9 % MPO positive patients and
14 % of ANCA negative patients. These rates are lower
than those from most published long-term clinical studies
[5, 36]. This likely reflects the close monitoring of individ-
ual patients within a relatively small clinical service where
interpretation of minor symptoms and clinical markers
(urinalysis, C-reactive protein, serum creatinine, platelet
count, ANCA titre) in identifies minor disease relapses
leading to modifications of therapy that potentially prevent
more major disease activity.
Conclusions
Overall, our data show the benefits in developing a spe-
cialised clinical service for AAV, especially for the elderly
population. Our disease remission and relapse rates, as
well as adverse events, compare favourably with other
published studies. Our modified use of PEX as part of dis-
ease induction therapy to incorporate those patients with
histological evidence of severe renal disease suggests en-
couraging responses to treatment with no increase in ad-
verse events.
Limitations
We recognise the limitations of this work. Although the
numbers of patients in our study are similar to those in
previous published studies [9, 30, 37] the number is still
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reasonably low with likely inadequate statistical power to
detect the benefits of PEX. Furthermore, this was a retro-
spective review and not a randomised clinical trial but the
eagerly awaited results of the on-going PEXIVAS study
[38], which extends PEX to patients with an eGFR <50 ml/
min, should help to further clarify its role in the therapeutic
armamentarium of AAV.
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